Journal of Pain and Symptom Management
Volume 35, Issue 4 , Pages 420-429 , April 2008

Tetrodotoxin for Moderate to Severe Cancer Pain: A Randomized, Double Blind, Parallel Design Multicenter Study

  • Neil A. Hagen, MD, FRCPC

      Affiliations

    • Division of Palliative Medicine, Department of Oncology, University of Calgary and Alberta Cancer Board, Calgary, Alberta
    • Corresponding Author InformationAddress correspondence to: Neil A. Hagen, MD, FRCPC, Department of Oncology, University of Calgary, 1331-29 Street NW, Calgary, Alberta, Canada T2N 4N2.
    • ,
  • Patrick du Souich, MD, PhD

      Affiliations

    • Department of Pharmacology, Faculty of Medicine, University of Montréal, Montréal, Québec
    • ,
  • Bernard Lapointe, MD

      Affiliations

    • Palliative Care Program, Sir Mortimer B. Davis – Jewish General Hospital, Montréal, Québec
    • ,
  • May Ong-Lam, MD, FRCPC

      Affiliations

    • St. Paul's Hospital, Vancouver, British Columbia
    • ,
  • Benoit Dubuc, MD

      Affiliations

    • Pain Clinic, CHUM – Hotel Dieu, Montréal, Québec
    • ,
  • David Walde, MD, FRCPC

      Affiliations

    • Algoma Regional Cancer Program/Sault Area Hospital, Sault Ste. Marie, Ontario
    • ,
  • Robin Love, MD, CCFP

      Affiliations

    • Nanaimo Regional General Hospital, Nanaimo, British Columbia
    • ,
  • Anh Ho Ngoc, PhD

      Affiliations

    • Wex Pharmaceuticals, Vancouver, British Columbia, Canada
    • ,
  • on Behalf of the Canadian Tetrodotoxin Study Group

,Accepted 4 June 2007.

References 

  1. Mantyh PW. Cancer pain and its impact on diagnosis, survival and quality of life. Nat Rev Neurosci. 2006;7:797–809
  2. Wells N. Pain intensity and pain interference in hospitalized patients with cancer. Oncol Nurs Forum. 2000;27:985–991
  3. Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol. 2002;249:9–17
  4. Poleshuck EL, Katz J, Andrus CH, et al. Risk factors for chronic pain following breast cancer surgery: a prospective study. J Pain. 2006;7:626–634
  5. de Stoutz ND, Bruera E, Suarez-Almazor M. Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage. 1995;10:378–384
  6. Trescot AM, Boswell MV, Atluri SL, et al. Opioid guidelines in the management of chronic non-cancer pain. Pain Physician. 2006;9:1–39
  7. Mystakidou K, Parpa E, Katsouda E, Galanos A, Vlahos L. Pain and desire for hastened death in terminally ill cancer patients. Cancer Nurs. 2005;28:318–324
  8. O'Mahony S, Goulet J, Kornblith A, et al. Desire for hastened death, cancer pain and depression: report of a longitudinal observational study. J Pain Symptom Manage. 2005;29:446–457
  9. Woodward D. Developing a pain management program through continuous improvement strategies. J Nurs Care Qual. 2005;20:261–267
  10. Ross JR, Riley J, Quigley C, Welsh KI. Clinical pharmacology and pharmacotherapy of opioid switching in cancer patients. Oncologist. 2006;11:765–773
  11. Omana-Zapata I, Khabbaz MA, Hunter JC, Clarke DE, Bley KR. Tetrodotoxin inhibits neuropathic ectopic activity in neuromas, dorsal root ganglia and dorsal horn neurons. Pain. 1997;72:41–49
  12. Lyu YS, Park SK, Chung K, Chung JM. Low dose of tetrodotoxin reduces neuropathic pain behaviors in an animal model. Brain Res. 2000;871:98–103
  13. Marcil J, Walczak JS, Guindon J, et al. Antinociceptive effects of tetrodotoxin (TTX) in rodents. Br J Anaesth. 2006;96:761–768
  14. Amir R, Argoff CE, Bennett GJ, et al. The role of sodium channels in chronic inflammatory and neuropathic pain. J Pain. 2006;7(5 Suppl 3):S1–S29
  15. Hagen NA, Fisher KM, Lapointe B, et al. on behalf of the Canadian Tetrodotoxin Study Group An open-label, multi-dose efficacy and safety study of intramuscular tetrodotoxin in patients with severe cancer-related pain. J Pain Symptom Manage. 2007;34(2):171–182
  16. Galer BS, Jensen MP. Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale. Neurology. 1997;48:332–338
  17. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994;23:129–138
  18. Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain. 2005;113:9–19
  19. Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain. 1975;1:277–299
  20. Chaplan SR, Bach FW, Shafer SL, Yaksh TL. Prolonged alleviation of tactile allodynia by intravenous lidocaine in neuropathic rats. Anesthesiology. 1995;83:775–785
  21. Araujo MC, Sinnott CJ, Strichartz GR. Multiple phases of relief from experimental mechanical allodynia by systemic lidocaine: responses to early and late infusions. Pain. 2003;103:21–29
  22. Bruera E, Ripamonti C, Brenneis C, Macmillan K, Hanson J. A randomized double-blind crossover trial of intravenous lidocaine in the treatment of neuropathic cancer pain. J Pain Symptom Manage. 1992;7:138–140
  23. Challapalli V, Tremont-Lukats IW, McNicol ED, Lau J, Carr DB. Systemic administration of local anesthetic agents to relieve neuropathic pain. Cochrane Database Syst Rev. 2005 Oct 19;4:CD003345
  24. Dellemijn PL, Vanneste JA. Randomised double-blind active-placebo-controlled crossover trial of intravenous fentanyl in neuropathic pain. Lancet. 1997;349:753–758
  25. Farrar JT, Cleary J, Rauck R, Busch M, Nordbrock E. Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst. 1998;90:611–616
  26. Caraceni A, Zecca E, Bonezzi C, et al. Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. J Clin Oncol. 2004;22:2909–2917
  27. du Souich P, Lu S, Ngoc AH. Tetrodotoxin (TTX) in the management of pain in animals and humans with cancer (Abstract). Pharmacologist. 2002;44:A59
  28. du Souich P, Sellers EM, Kaplan HL, et al. Comparison of adverse drug effects (ADEs) of tetrodotoxin (TTX) in healthy volunteers with the analgesic effect in patients (Abstract). Clin Pharmacol Ther. 2002;71:16
  29. Sellers EM, Romach MK, Ngoc AH, et al. Pharmacologic effects and safety of single and multiple doses of tetrodotoxin (TTX) (Abstract). Clin Pharmacol Ther. 2002;71:16
  30. Breitbart W, Rosenfeld B, Pessin H, et al. Depression, hopelessness, and desire for hastened death in terminally ill patients with cancer. JAMA. 2000;284:2907–2911
  31. Chochinov HM, Wilson KG, Enns M, et al. Desire for death in the terminally ill. Am J Psychiatry. 1995;152:1185–1191
  32. Sittl R, Griessinger N, Likar R. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther. 2003;25:150–168
  33. Wiffen PJ, McQuay HJ, Edwards JE, Moore RA. Gabapentin for acute and chronic pain. Cochrane Database Syst Rev. 2005;3:CD005452
  34. Ross JR, Goller K, Hardy J, et al. Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study. J Palliat Med. 2005;8:1118–1126
  35. Wiffen PJ, McQuay HJ, Moore RA. Carbamazepine for acute and chronic pain. Cochrane Database Syst Rev. 2005;3:CD005451

 This study was funded by WEX Pharmaceuticals Inc.

PII: S0885-3924(07)00744-0

doi: 10.1016/j.jpainsymman.2007.05.011

Journal of Pain and Symptom Management
Volume 35, Issue 4 , Pages 420-429 , April 2008

Article Tools

* Image Usage & Resolution